1 completed, 1 withdrawn. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Withdrawn 1 |
Follow Complicated Urinary Tract Infections: new trials by email Literature Review of Complicated Urinary Tract Infections trials Research Report on Complicated Urinary Tract Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| LYS228 PK, Clinical Response, Safety and Tolerability in Patients With Complicated Urinary Tract Infection (cUTI) LYS228, Standard of care therapy - Complicated Urinary Tract Infections | Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2018-10-19 | 2018-10-26 | |
| Evaluation of Safety, Pharmacokinetics and Efficacy of Ceftazidime and Avibactam (CAZ-AVI ) Compared With Cefepime in Children From 3 Months to Less Than 18 Years of Age With Complicated Urinary Tract Infections (cUTIs) Ceftazidime -avibactam, Cefepime - Complicated Urinary Tract Infections | Phase 2 | Completed | Pfizer | 97 | 2015-09-24 | 2018-07-11 |
Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Infections (1) · Male Urogenital Diseases (1) · Urogenital Diseases (1) · Urologic Diseases (1)
Cefepime (1) · avibactam, ceftazidime drug combination (1)
Novartis Pharmaceuticals (1) · Pfizer (1)
Greece (2) · United States (2) · Czechia (1) · Denmark (1) · Hungary (1) · Poland (1) · Romania (1) · Russia (1) · Taiwan (1) · Turkey (Türkiye) (1)
PMID 30061293, PMID 31335570, PMID 34687548
2014 (1)